Matinas BioPharma Holdings Operating Income Growth & History (MTNB)

Matinas BioPharma Holdings's operating income was −$7.0M for fiscal 2025.

View full Matinas BioPharma Holdings company overview

Matinas BioPharma Holdings annual operating income history

Matinas BioPharma Holdings annual operating income

Fiscal yearPeriod endedOperating incomeChangeGrowth
20252025-12-31−$7.0M$17.6M
20242024-12-31−$24.6M−$827,000
20232023-12-31−$23.8M$824,000
20222022-12-31−$24.6M$145,000
20212021-12-31−$24.7M−$528,448
20202020-12-31−$24.2M−$5.3M
20192019-12-31−$18.9M−$4.3M
20182018-12-31−$14.6M$1.9M
20172017-12-31−$16.5M−$8.2M
20162016-12-31−$8.3M$1.7M
20152015-12-31−$9.9M$553,500
20142014-12-31−$10.5M−$6.8M
20132013-12-31−$3.7M

Matinas BioPharma Holdings operating income trends

Over the last five fiscal years, Matinas BioPharma Holdings's operating income increased from −$24.2M to −$7.0M, a change of $17.2M. The latest reported quarter, Q2 2026, shows −$1.6M.

About the metric

What operating income means

Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.

Calculation and source

SEC-reported operating income

TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Matinas BioPharma Holdings source filings ↗

Community posts

It’s quiet here.

No posts about MTNB yet. Start the conversation.

Write the first post